Jafron Biomedical Co.,Ltd.

Shenzhen Stock Exchange 300529.SZ

Jafron Biomedical Co.,Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 11.68

Jafron Biomedical Co.,Ltd. Price to Sales Ratio (P/S) is 11.68 on January 14, 2025, a 41.74% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Jafron Biomedical Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 15.49 on October 08, 2024, which is 32.57% above the current Price to Sales Ratio (P/S).
Jafron Biomedical Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 6.78 on February 05, 2024, which is -42.01% below the current Price to Sales Ratio (P/S).
Jafron Biomedical Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 10.80.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 300529.SZ

Jafron Biomedical Co.,Ltd.

CEO	Mr. Fan Dong
IPO Date	Aug. 2, 2016
Location	China
Headquarters	No. 98 Keji 6th Road
Employees	2,408
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Medical Instruments

Description

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.

Key trends

Past 5 years